Redeye comments on Embracer’s Q4-report which saw lower topline than expected while adjusted EBIT wa...
Kapsaicinproducenten XP Chemistries EU-ansökan till EFSA (European Food Safety Authority) genomgick ...
Positive growth outlook for margin-accretive Water segment.
Redeye notes that Neonode's strategic shift has resulted in a first license agreement for it's touch...
Expect continued M&A, mainly in Germany 6% adj. EBITA CAGR '23-'26e, M&A to support 10% growth 12-9x...
Redeye leaves its comments on today's press release from Xbrane confirming the succesful scale up of...
Redeye notes that a new German clinical study has been published, presenting the improvement the Nev...
Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduc...
Redeye comments on the critical financial situation of Amniotics and the rejection of the acquisitio...
Organic sales decline of 11% y-o-y EBIT margin of 8.
Redeye retains its positive view of Vertiseit following a directed share issue.
Alisa Bank completed the combination with PURO Finance and issued a guidance for 2024.
Late last night, NoHo Partners updated its financial targets for the strategy period 2025-2027.
Redeye provides a short research note following Scandinavian ChemoTech's anouncement of its first or...
Redeye comments on the new multi-year agreement that Dignitana has signed with Konica Minolta in Jap...
Redeye comments on Modelon's proposed rights issue, which will provide the company with a good cushi...
Redeye provides a research update following the Q1 2024 report from Respiratorius.
We have talked to Lagercrantz's CEO, Jörgen Wigh, and VP Niche Products Divsion, Jonas Ahlberg, abou...
Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting...
CEPS miss on one-off tax item Halving hybrid leads to higher CEPS '24e-'26e CEPS CAGR of ~14% vs sec...
